Research-Grade Proteins Market Report 2026

The research-grade proteins market size has grown exponentially in recent years. It will grow from $1.33 billion in 2025 to $1.61 billion in 2026 at a compound annual growth rate (CAGR) of 20.8%. The growth in the historic period can be attributed to growth of academic life sciences research, increasing use of proteins in molecular biology experiments, expansion of biopharmaceutical r&d activities, availability of recombinant protein expression systems, rising funding for basic biomedical research.

The research-grade proteins market size is expected to see rapid growth in the next few years. It will grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 18.6%. The growth in the forecast period can be attributed to increasing focus on precision medicine research, rising demand for protein-based drug targets, growth in cell and gene therapy research, expanding use of proteins in structural biology, increasing outsourcing of research activities by pharma companies. Major trends in the forecast period include rising demand for high-purity proteins in drug discovery research, growing use of recombinant proteins in cell and molecular biology studies, increasing adoption of research-grade proteins in immunology and oncology research, expansion of protein-based assays and functional studies, higher preference for custom and application-specific proteins.

The increasing number of clinical trials is anticipated to drive the expansion of the research-grade proteins market. Clinical trials are research studies that examine the safety and effectiveness of new medical treatments, interventions, or devices in humans. The rise in the number of clinical trials is attributed to advancements in medical research, the burden of diseases, changes in regulations, patient demand, and industry investments. Research-grade proteins support clinical trials by acting as crucial tools for biomarker development, assay creation, drug target identification, quality control, and reference standards, ensuring the precision and reliability of experimental results. For example, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the number of pharmaceutical industry trials initiated in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Consequently, the rising number of clinical trials is fueling the growth of the research-grade proteins market.

Major companies operating in the research-grade proteins market are concentrating on developing innovative solutions such as high-purity, animal-origin-free recombinant proteins to enhance consistency, safety, and performance in advanced cell and gene therapy processes. High-purity, animal-origin-free recombinant proteins are laboratory-produced proteins made without any animal-derived components and purified to very high standards to ensure reliability, safety, and consistency for research and therapeutic uses. For example, in October 2025, Qkine Ltd., a UK-based manufacturing company, introduced a new range of Cell Therapy Grade recombinant proteins designed to meet the strict requirements of cell therapy research, process development, and GMP manufacturing. These high-purity, animal-origin-free proteins provide low endotoxin levels and minimal host cell contaminants and are manufactured following defined standards with complete regulatory documentation. Their consistent performance enables seamless scalability from early research to GMP clinical processes. Intended for advanced applications such as CAR-T, iPSC differentiation, and ex vivo gene editing, these regulatory-ready proteins help accelerate therapy development while minimizing risk.

In December 2023, Danaher Corporation, a US-based science and technology company, acquired Abcam plc for approximately $5.7 billion, paying $24.0 per share in cash. With this acquisition, Danaher aims to strengthen its presence in the protein consumables market and enhance its technological capabilities in proteomics to accelerate drug discovery and diagnostics. Abcam Limited, a UK-based life-sciences technology company, specializes in highly validated antibodies, reagents, biomarkers, and assays used by researchers worldwide to study complex biological pathways.

Major companies operating in the research-grade proteins market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Bio-Techne, Stemcell Technologies Inc., Miltenyi Biotec, GenScript Biotech Corporation, Sino Biological Inc., ACROBiosystems, OriGene Technologies Inc., RayBiotech Inc., Rockland Immunochemicals Inc., Proteintech Group Inc., Novus Biologicals LLC, Active Motif, Aviva Systems Biology Corporation, StressMarq Biosciences Inc., Abnova Corporation, AnaSpec, Biomatik, Prospec-Tany Technogene Ltd., Cusabio Technology LLC, United States Biological, Laurus Bio, Boster Biological Technology, AMS Biotechnology Europe Ltd (AMSBIO)

North America was the largest region in the research-grade proteins market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the research-grade proteins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the research-grade proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the research-grade proteins market by increasing costs associated with imported raw materials, expression systems, purification resins, and cold-chain logistics required for protein stability. These effects are most pronounced in regions reliant on cross-border life sciences supply chains, particularly Asia-Pacific and emerging research hubs. Higher tariffs can raise procurement costs for academic institutes and biotech firms, potentially slowing research timelines. Conversely, tariffs have encouraged regional protein manufacturing capabilities and localized production, improving supply resilience and reducing long-term import dependence.

The research-grade proteins market research report is one of a series of new reports that provides research-grade proteins market statistics, including research-grade proteins industry global market size, regional shares, competitors with a research-grade proteins market share, detailed research-grade proteins market segments, market trends and opportunities, and any further data you may need to thrive in the research-grade proteins industry. This research-grade proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Research-grade proteins are proteins that are produced and purified to meet high standards of quality and purity for use in scientific research. These proteins are employed in a wide range of experimental and analytical applications, including investigations in molecular biology, biochemistry, cell biology, and drug development. They serve as crucial tools for studying protein function, interactions, structure, and for aiding the development of new therapeutic strategies.

The primary products of research-grade proteins include cytokines and growth factors, antibodies, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Cytokines and growth factors are proteins that control cell signaling and immune responses in the body. The host cells, such as mammalian cells, bacterial cells, fungi and yeast, insect cells, and others, are utilized by pharmaceutical and biotechnology companies, academic and research institutes, and others.

The research-grade proteins market consists of sales of bovine serum albumin (BSA), recombinant human insulin, recombinant human epidermal growth factor (EGF), recombinant human tumor necrosis factor-alpha, recombinant human interferon-gamma (IFN-gamma). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.